Nightstar Therapeutics Ltd. has become the first life sciences company founded by UK healthcare investment company Syncona to be publicly listed, a milestone that gives some reassurance that Syncona's strategy of founding and supporting companies long-term is working for investors, and patients.
The London-based group was set up in 2013 by Syncona and Robert MacLaren, professor of ophthalmology at the University of Oxford, to develop gene therapies to treat inherited retinal diseases, and was listed on Sept. 28 on the US NASDAQ exchange